Cingulate Inc.
Cingulate Inc. (CING): 2 pipeline candidates · 2 upcoming catalysts · ~12 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.5 months
D/E 0.64 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~228d
4 buys · 0 sells (180d)
A transparent, data-derived signal for Cingulate Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$63.8M
Cash
$25.9M
Quarterly Burn
$6.9M
Runway
11.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ctx-1301 | Phase 3 |
| ctx-1301 - dexmethylphenidate | Phase 3 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
23
Total value held
$7.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 617,934 | $3.8M |
| geode capital management, llc | 101,373 | $630K |
| marshall wace, llp | 92,934 | $577K |
| jane street group, llc | 90,867 | $564K |
| xtx topco ltd | 53,503 | $332K |
| bcv asset management inc. | 51,200 | $318K |
| vanguard fiduciary trust co | 50,074 | $311K |
| renaissance technologies llc | 31,888 | $198K |
| state street corp | 27,588 | $171K |
| blackrock, inc. | 23,269 | $145K |
Showing top 10 of 23 institutional holders of Cingulate Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cingulate Inc.'s pipeline?
Cingulate Inc. (CING) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cingulate Inc.'s lead drug candidate?
Cingulate Inc.'s most advanced tracked candidate is ctx-1301 (Phase 3) for ADHD.
What is Cingulate Inc.'s next catalyst?
Cingulate Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safet" — expected February 1, 2027.
What is Cingulate Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cingulate Inc. has approximately 11.5 months of cash runway.
What is Cingulate Inc.'s market capitalization?
Cingulate Inc.'s market capitalization is approximately $63.8M.
Get the full picture on Cingulate Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.